Generate Biomedicines

Generate Biomedicines aims to gain an ability to quickly develop new medicines for various applications based on extensive research on how proteins work. The company has numerous drugs in the pipeline, including several projects in collaboration with Amgen.

NewsHeat chart

  • Week
  • Month
  • Year
  • Media news
  • Corp news
  • Combo news

The data in the chart above is based on data derived from our proprietary XP calculation model and may be changed, adjusted and updated without prior notice

Company Valuation

  • Valuation
  • Share Price
  • Cumulative Funding

The data in the tables and charts is based on data from public sources and although we make every effort to compile the data, it may not coincide with the actual data of the issuer.

Funding Round
Funding Amount
Post-Money Valuation
$  Share Price
Series C14 Sep 2023
Series B18 Nov 2021
Series A10 Sep 2020

*** - To view the data, please log into your account or create a new one.

Company valuation calculator

To calculate, specify one of the parameters


T. Rowe PriceT. Rowe Price
Fidelity Management and Research CompanyFidelity Management and Research Company

News related to Generate Biomedicines

Generate BiomedicinesGenerate Biomedicines • 16 Nov 2023

Generate:Biomedicines Announces Publication of its Chroma Model ...

SOMERVILLE, Mass., November 15, 2023--Generate:Biomedicines today announced a publication in Nature describing Chroma, a generative AI model that canĀ ...
Generate BiomedicinesGenerate Biomedicines • 14 Oct 2023

Generate:Biomedicines Announces Close of $273M Series C Financing to Advance Its Generative AI Pipeline

Our Series C round further propels The Generate Platform to increase significantly the precision, speed, and probability of success of novel therapeutics ...,million%20in%20Series%20C%20financing.

Generate Biomedicines Twitter